Targeting receptor-biased signaling to drive synaptogenesis.
Through targeted structural modifications and predictive in-silico modeling, our platform is designed to investigate whether neuroplasticity-related signaling can be separated from classical hallucinogenic activity.
Over 280 million people worldwide live with major depressive disorder. Decades of approved therapies have been constrained by delayed onset, incomplete response rates, and treatment resistance. Emerging evidence suggests structural neuroplasticity may represent a distinct therapeutic axis — addressing underlying neurobiological dysfunction rather than symptom modulation alone.
Virtual screening and molecular docking against active-state receptor conformations. Our predictive models evaluate orthosteric binding motifs associated with differential receptor conformational states relevant to downstream signaling bias.
PDB: 6WHA — 5-HT2A Active StateDetailed mapping of electrostatic and hydrogen-bond interactions within the orthosteric binding pocket. Structural analysis explores the relationship between receptor activation profiles and neuroplasticity-associated signaling pathways (Gq vs. β-arrestin2 recruitment).
Coordinating with specialized Contract Research Organizations (CROs) to validate custom chemical synthesis routes and establish standardized in-vitro neural assay workflows for primary neuronal culture and pathway activation readouts.
Bilan Synaptics targets fundamental synaptic atrophy through computationally analyzed functional scaffolds optimized for specific active-state structural interactions.
The lead compound series is designed to target specific receptor conformational states. Evaluating whether this computationally predicted profile translates to neuroplasticity-associated signaling — while assessing hallucinogenic liability via differential β-arrestin / Gq recruitment — is the primary focus of our upcoming in-vitro validation phase.
Founded by Nina Lukianov Bilan & Nikita Bilan, Bilan Synaptics operates as a lean, agile, founder-led virtual research initiative designed to bridge chemical design hypotheses and experimental validation.
By avoiding upfront physical laboratory buildout, we adopt an efficient virtual operating model — leveraging a growing network of external scientific consultants, specialist advisors, and world-class Contract Research Organizations (CROs) to systematically test our structural assets.
Virtual library screening, pharmacophore modeling, ADMET toxicity prediction, and molecular docking against 5-HT2A active-state crystal structure.
Evaluating chemical synthesis partners and designing scalable, multi-step synthesis routes for lead compound validation.
Primary neuronal culture assays to assess structural plasticity, β-arrestin2 bias, and Gq pathway activation in parallel readouts.